Nephrology

Every comorbidity related to diabetes causes life expectancy to plummet and medical costs to soar.

Patients had significant reduction in urinary albumin-to-creatinine ratio (UACR) in the first six months of using dapagliflozin.

Cardiovascular and renal disease burdens also occur in type 1 diabetes.

Diabetes is the leading cause of chronic kidney disease due to microvascular damage to the renal blood vessels.

Finerenone is a mineralocorticoid receptor antagonist indicated for chronic kidney disease (CKD) with type 2 diabetes. Does the use of insulin affect its performance against kidney and cardiovascular issues?

With the introduction of this glucagon-like peptide-1 receptor agonist (GLP-1 RA), efpeglenatide, could we see new cardiovascular and renal benefits for patients with type 2 diabetes?

After starting SGLT-2i, is the discontinuation of therapy necessary if there is an immediate decline in estimated Glomerular Filtration Rate (eGFR) in patients?

Metformin, used in the management of blood glucose, may provide a renoprotective effect through inhibition of inflammation and apoptosis.

Researchers discovered that dapagliflozin helped patients with and without diabetes in improving kidney disease.

Study found children with a new diagnosis of type 1 diabetes experienced higher rates of diabetic ketoacidosis in the COVID-19 pandemic.